STOCKWATCH: Gilead damned for doing the right thing
This article was originally published in Scrip
Executive Summary
The last thing you need on a Friday afternoon is for one of your biotech holdings to open the trading session down by more than 7%. And as the company in question was the large capitalization and profitable antiviral specialist Gilead Sciences, I did wonder if a new global conflict rather than a Ukrainian ceasefire had just been announced. But in this case, the news that took Gilead's share price down was entirely of its own making and, even worse, the reaction was in response to Gilead's best of intentions.